PUBLICATION:
Biomark Insights. 2016; 11: 139–146. doi: 10.4137/BMI.S38435
AUTHORS: 
Inès J. Beumer, Marion Persoon, Anke Witteveen, Christa Dreezen, Suet-Feung Chin, Stephen-John Sammut, Mireille Snel, Carlos Caldas, Sabine Linn, Laura J. van ’t Veer, Rene Bernards, and Annuska M. Glas
SUMMARY:
Pooled analysis. Study results validate MammaPrint as an independent factor for breast cancer patients with early-stage invasive lobular breast cancer. Hazard ratios up to 11 in multivariate analyses emphasize the independent value of MammaPrint, specifically in lymph node-negative ILC breast cancers.
Read more: Beumer et al_2016_Biomarker Insights_Prognostic Value of MammaPrint®…
